Clinical Trial Update: Observation of Treatment Patterns With Lucentis in Approved Indications

View source ↗

Summary

An observational study examining how Lucentis is used in approved indications such as neovascular age-related macular degeneration and diabetic macular edema.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Branch Retinal Vein Occlusion
• Central Retinal Vein Occlusion
• Choroidal Neovascularization
• Diabetic Macular Edema
• Neovascular Age-related Macular Degeneration

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Neovascular AMD, Visual Impairment Due to DME, Visual Impairment Due to Macular Oedema Secondary to Branch or Central RVO, Visual Impairment Due to CNV | Status: COMPLETED